Fig 1.
CONSORT Flowchart for Study 1 (Study Protocol 13004)
Fig 2.
CONSORT Flowchart for Study 2 (Study Protocol 13005)
Fig 3.
Summary of Study Design for both studies
Table 1.
Patient Diary Recorded Reactogenicity Following Dose 1 and Dose 2 of Vaccine Pooled Data.
Table 2.
Physician Examination Reactogenicity in the 7 Days Following Dose 1 and Dose 2 of Vaccine Pooled Data.
Table 3.
Overall summary of frequency of adverse events by treatment group.
Table 4.
Serum HAI antibody responses at Day 39±3 following first nasal administration of trivalent Proteosome-influenza vaccine.
Table 5.
Nasal virus-specific secretory IgA responses at Day 39±3 after first nasal administration of trivalent Proteosome influenza vaccine.
Fig 4.
Percentage vaccine efficacy by treatment group
Table 6.
Proportion of subjects in each treatment group meeting specified post-challenge endpoints and apparent efficacy versus Placebo (pooled data).
Table 7.
Incidence of Post-Challenge Symptoms on Days 42–49 by Dose: Pooled Data.
Fig 5.
Mean (± SE) Tissue count and tissue weight for all treatment groups in Study 2
Fig 6.
Correlation of serum IgG (HAI) and mucosal sIgA levels at Day 39±3 and rates of any influenza symptoms and seroconversion following viral challenge